Skip to main content

General features and epidemiology of lymphoma in Colombia. A multicentric study


The relative frequency of the non-Hodgkin lymphoma (NHL) subtypes varies around the world. The objective of this study was to describe the general features of patients with lymphoma in Colombia. A total of 819 patients with a new diagnosis of lymphoma were included. Nighty-nine (12 %) of them had Hodgkin lymphoma (HL) and 720 (88 %) had NHL. Most cases had advanced stage disease at presentation (63.6 %). Diffuse large B cell lymphoma (DLBCL) was the most frequent diagnosis; it was seen in 40 % of patients with NHL and in 35 % of patients in the whole series. Overall survival rates at 3 years were 77 % for HL and follicular lymphoma, 54 % for DLBCL, and 45 % for T cell lymphomas. In conclusion, the distribution of specific NHL subtypes is similar to what has been reported previously in other tropical countries.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. Swerdlow SH (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn (International Agency for Research on Cancer. World Health Organization, Lyon

    Google Scholar 

  2. Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 9:717–720

    Article  CAS  PubMed  Google Scholar 

  3. Vose J, Armitage J (2008) Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130

    Article  PubMed  Google Scholar 

  4. Yang QP, Zhang WY, Yu JB et al (2011) Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 6:77

    Article  PubMed Central  PubMed  Google Scholar 

  5. Yoon SO, Suh C, Lee DH et al (2010) Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 85:760–764

    Article  PubMed  Google Scholar 

  6. Murillo RH, Piñeros M, Acosta JA, Castellanos VH (2012) Instituto Nacional de Cancerología Anuario Estadístico 2010. Volumen 8 (Instituto Nacional de Cancerología: Bogotá, Colombia)

  7. Cheson BD, Pfistner B, Juweid ME (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–86

    Article  PubMed  Google Scholar 

  8. Parkin DM (2006) The evolution of the population-based cancer registry. Nat Rev Cancer 6:603–612

    Article  CAS  PubMed  Google Scholar 

  9. Townsend W, Linch D (2012) Hodgkin's lymphoma in adults. Lancet 380:836–847

    Article  PubMed  Google Scholar 

  10. Roman E, Smith AG (2011) Epidemiology of lymphomas. Histopathology 58:4–14

    Article  PubMed  Google Scholar 

  11. Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848–857

    Article  PubMed  Google Scholar 

  12. Novelli S, Briones J, Sierra J (2013) Epidemiology of lymphoid malignancies: last decade update. Springerplus 2:70

    Article  PubMed Central  PubMed  Google Scholar 

  13. Luminari S, Cesaretti M, Rashid I et al (2007) Incidence, clinical characteristics and survival of malignant lymphomas: a population based study from cancer registry in northern Italy. Hematol Oncol 25:189–197

    Article  PubMed  Google Scholar 

  14. Laurini J, Perry A, Boilesen E et al (2012) Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 120:4795–4801

    Article  CAS  PubMed  Google Scholar 

  15. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265–76

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Montoto S, Fitzgibbon J (2011) Transformation of Indolent B-Cell Lymphomas. J Clin Oncol 29:1827–34

    Article  PubMed  Google Scholar 

  17. Perry AM, Molina-Kirsch KH, Nathwani BN et al (2011) Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. Leuk Lymphoma 52:1681–1688

    Article  PubMed  Google Scholar 

  18. Morrow RH Jr (1985) Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt's lymphoma. IARC Sci Publ 60:177–86

    PubMed  Google Scholar 

  19. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328–1337

    Article  CAS  PubMed  Google Scholar 

  20. Chene A, Donati D, Orem J et al (2009) Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol 19:411–20

    Article  CAS  PubMed  Google Scholar 

  21. Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386–95

    Article  CAS  PubMed  Google Scholar 

  22. Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–32

    Article  CAS  PubMed  Google Scholar 

  23. Sehn LH, Donaldson J, Chhanabhai M et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027–33

    Article  CAS  PubMed  Google Scholar 

  24. Cunningham D, Hawkes EA, Jack A et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381:1817–26

    Article  CAS  PubMed  Google Scholar 

  25. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–74

    Article  CAS  PubMed  Google Scholar 

  26. Shenoy PJ, Malik N, Nooka A et al (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117:2530–40

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Marcos Arango.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Combariza, J.F., Lombana, M., Torres, A.M. et al. General features and epidemiology of lymphoma in Colombia. A multicentric study. Ann Hematol 94, 975–980 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Lymphoma
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Colombia